氰基丙烯酸酯闭合术与射频消融术治疗大隐静脉功能不全的随机试验24个月结果
VeClose随机多中心试验纳入222例有症状的大隐静脉功能不全患者,随机接受氰基丙烯酸酯闭合术(CAC,n=108)或射频消融术(RFA,n=114)。24个月时CAC组完全闭合率95.3%,RFA组94.0%,CAC持续非劣于RFA(P=.0034)。两组症状和生活质量改善相似,无临床显著的器械或操作相关晚期不良事件。
要点
- 24个月完全闭合率CAC组95.3% vs RFA组94.0%,CAC持续非劣于RFA(P=.0034)。
- 两组症状和生活质量改善相似,无临床显著的器械或操作相关晚期不良事件。
- 作者认为CAC治疗大隐静脉功能不全是安全且持久的,随访至2年。
核心结论
- CAC和RFA均能有效闭合目标大隐静脉,至24个月时两组患者生活质量改善相似且显著。
- 作者认为CAC治疗大隐静脉功能不全是安全且持久的,随访至2年。
研究设计与样本
- 随机、多中心临床试验(VeClose),纳入222例有症状的大隐静脉功能不全患者,随机接受CAC(n=108)或RFA(n=114)。
- 3个月随访前不允许对属支静脉曲张进行辅助治疗;治疗后第3天及第1、3、6、12、24个月行目标静脉双功超声检查,由治疗医师评估闭合情况。
主要发现
- 222例随机患者中171例完成24个月随访,包括CAC组87例和RFA组84例。
- 24个月完全闭合率CAC组95.3% vs RFA组94.0%,CAC持续非劣于RFA(P=.0034)。
- 两组症状和生活质量改善相似。
- 无临床显著的器械或操作相关晚期不良事件发生。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We previously reported 3-month and 12-month occlusion rates after treatment of clinically symptomatic saphenous vein reflux with either cyanoacrylate closure (CAC) using the VenaSeal Closure System (Medtronic, Dublin, Ireland) or radiofrequency ablation (RFA) in a randomized, multicenter, clinical trial, VenaSeal Sapheon Closure System vs Radiofrequency Ablation for Incompetent Great Saphenous Veins (VeClose). Herein we report the 24-month follow-up results of the VeClose trial. METHODS: There were 222 patients with symptomatic great saphenous vein (GSV) incompetence who were randomly assigned to receive either CAC (n = 108) or RFA (n = 114). Patients were not allowed to receive adjunctive treatment of tributary varicosities until after the 3-month visit. Duplex ultrasound of the target vein was performed at day 3 and months 1, 3, 6, 12, and 24 after treatment, and closure was assessed by ultrasound by the treating physician. Overall 24-month success rates were compared; in addition, time to first reopening of the target vein was evaluated using survival analysis. End points such as Venous Clinical Severity Score, EuroQoL-5 Dimension, and Aberdeen Varicose Vein Questionnaire were evaluated. RESULTS: Of 222 randomized patients, 171 completed the 24-month follow-up, which included 87 from the CAC group and 84 from the RFA group. The 24-month complete closure rate was 95.3% in the CAC group and 94.0% in the RFA group, demonstrating continued noninferiority of CAC compared with RFA (P = .0034). Symptoms and quality of life improved similarly in both groups. No clinically significant device- or procedure-related late adverse events occurred. CONCLUSIONS: Both CAC and RFA were effective in closure of the target GSV, resulting in similar and significant improvements in the patient's quality of life through 24 months. These results suggest that CAC of the GSV is safe and durable out to 2 years.
引用
- Gibson K, Morrison N, Kolluri R, et al. Twenty-four month results from a randomized trial of cyanoacrylate closure versus radiofrequency ablation for the treatment of incompetent great saphenous veins. J Vasc Surg Venous Lymphat Disord. 2018. PMID: 29914814. doi:10.1016/j.jvsv.2018.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。